FGFR3 INHIBITOR COMPOUNDS

The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or ca...

Full description

Saved in:
Bibliographic Details
Main Authors METCALF, Andrew Terrance, WALLS, Shane Michael, CONDROSKI, Kevin Ronald, DILGER, Andrew Karl, ABRAHAM, Adedoyin David, KERCHER, Timothy Scott, URKALAN, Kaveri Balan, HAZLITT, Robert Alan, BUME, Desta Doro
Format Patent
LanguageEnglish
French
Published 09.09.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer. La présente invention concerne des composés de formule : destinés à être utilisés dans le traitement de la sclérodermie généralisée, de la fibrose (par exemple, la fibrose pulmonaire), l'achondroplasie, la dysplasie thanatophore (par exemple, de type I), l'achondroplasie sévère avec un retard de développement et une acanthosis nigricans (SADDAN), le syndrome de Muenke ou le cancer.
Bibliography:Application Number: WO2022US18644